Pulike Biological Engineering, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000025N0
CNY
14.03
-0.03 (-0.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

The company declared positive results in Mar'25 after very negative results in Dec'24

  • OPERATING CASH FLOW(Y) Highest at CNY 319.58 MM
  • RAW MATERIAL COST(Y) Fallen by -2.82% (YoY)
  • PRE-TAX PROFIT(Q) Highest at CNY 65.67 MM
2

With ROE of 5.41%, it has a very attractive valuation with a 1.83 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 4,457 Million (Small Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

4.75%

stock-summary
Debt Equity

-0.29

stock-summary
Return on Equity

5.79%

stock-summary
Price to Book

1.73

Revenue and Profits:
Net Sales:
277 Million
(Quarterly Results - Jun 2025)
Net Profit:
63 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.43%
0%
-0.43%
6 Months
-6.15%
0%
-6.15%
1 Year
13.51%
0%
13.51%
2 Years
-3.57%
0%
-3.57%
3 Years
-56.22%
0%
-56.22%
4 Years
-41.3%
0%
-41.3%
5 Years
-36.31%
0%
-36.31%

Pulike Biological Engineering, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.82%
EBIT Growth (5y)
3.16%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.43
Tax Ratio
7.96%
Dividend Payout Ratio
148.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.93%
ROE (avg)
8.20%

Valuation key factors

Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
1.83
EV to EBIT
25.83
EV to EBITDA
14.51
EV to Capital Employed
2.14
EV to Sales
3.70
PEG Ratio
3.76
Dividend Yield
2.96%
ROCE (Latest)
8.28%
ROE (Latest)
5.41%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.91% vs -0.83% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 19.66% vs 491.85% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "276.70",
          "val2": "274.20",
          "chgp": "0.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "97.50",
          "val2": "91.20",
          "chgp": "6.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "63.30",
          "val2": "52.90",
          "chgp": "19.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "243.00%",
          "val2": "222.10%",
          "chgp": "2.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.13% vs 1.71% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.82% vs 3.99% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,026.00",
          "val2": "1,238.10",
          "chgp": "-17.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "225.60",
          "val2": "267.00",
          "chgp": "-15.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "1.10",
          "chgp": "-72.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.00",
          "val2": "-17.70",
          "chgp": "49.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "92.80",
          "val2": "174.50",
          "chgp": "-46.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "102.60%",
          "val2": "142.00%",
          "chgp": "-3.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary

Jun'25
Mar'25
Change(%)
Net Sales
276.70
274.20
0.91%
Operating Profit (PBDIT) excl Other Income
97.50
91.20
6.91%
Interest
0.00
0.00
Exceptional Items
-0.60
-0.00
Consolidate Net Profit
63.30
52.90
19.66%
Operating Profit Margin (Excl OI)
243.00%
222.10%
2.09%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.91% vs -0.83% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 19.66% vs 491.85% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
1,026.00
1,238.10
-17.13%
Operating Profit (PBDIT) excl Other Income
225.60
267.00
-15.51%
Interest
0.30
1.10
-72.73%
Exceptional Items
-9.00
-17.70
49.15%
Consolidate Net Profit
92.80
174.50
-46.82%
Operating Profit Margin (Excl OI)
102.60%
142.00%
-3.94%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -17.13% vs 1.71% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.82% vs 3.99% in Dec 2023

stock-summaryCompany CV
About Pulike Biological Engineering, Inc. stock-summary
stock-summary
Pulike Biological Engineering, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available